BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest. 2010;120:1285-1297. [PMID: 20237413 DOI: 10.1172/jci36551] [Cited by in Crossref: 144] [Cited by in F6Publishing: 76] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012;7:29-54. [PMID: 22399234 DOI: 10.1007/s11523-012-0213-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
2 Ratikan JA, Micewicz ED, Xie MW, Schaue D. Radiation takes its Toll. Cancer Lett 2015;368:238-45. [PMID: 25819030 DOI: 10.1016/j.canlet.2015.03.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
3 Huck BR, Kötzner L, Urbahns K. Small Molecules Drive Big Improvements in Immuno-Oncology Therapies. Angew Chem Int Ed Engl 2018;57:4412-28. [PMID: 28971564 DOI: 10.1002/anie.201707816] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 16.3] [Reference Citation Analysis]
4 Zhou H, Luo M, Wen Y, Ma A, Luo Y, Yi Q, Chen J, Xiao L. [Expression of TLR5 in different types of non-small cell lung cancer cell lines and its activation mechanism]. Zhongguo Fei Ai Za Zhi 2015;18:8-15. [PMID: 25603867 DOI: 10.3779/j.issn.1009-3419.2015.01.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Yeh DW, Huang LR, Chen YW, Huang CF, Chuang TH. Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res 2016;2016:4368101. [PMID: 28116318 DOI: 10.1155/2016/4368101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
6 Koltsida O, Karamnov S, Pyrillou K, Vickery T, Chairakaki AD, Tamvakopoulos C, Sideras P, Serhan CN, Andreakos E. Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol Med 2013;5:762-75. [PMID: 23584892 DOI: 10.1002/emmm.201201891] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
7 Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2014;33:3485-3495. [PMID: 23934186 DOI: 10.1038/onc.2013.302] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 19.9] [Reference Citation Analysis]
8 Halmos B, Powell CA. Update in lung cancer and oncological disorders 2010. Am J Respir Crit Care Med 2011;184:297-302. [PMID: 21804121 DOI: 10.1164/rccm.201103-0370UP] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Drake MG, Kaufman EH, Fryer AD, Jacoby DB. The therapeutic potential of Toll-like receptor 7 stimulation in asthma. Inflamm Allergy Drug Targets 2012;11:484-91. [PMID: 23078048 DOI: 10.2174/187152812803589967] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
10 Monlish DA, Bhatt ST, Schuettpelz LG. The Role of Toll-Like Receptors in Hematopoietic Malignancies. Front Immunol 2016;7:390. [PMID: 27733853 DOI: 10.3389/fimmu.2016.00390] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
11 Patinote C, Karroum NB, Moarbess G, Cirnat N, Kassab I, Bonnet PA, Deleuze-Masquéfa C. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem 2020;193:112238. [PMID: 32203790 DOI: 10.1016/j.ejmech.2020.112238] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
12 Hotz C, Treinies M, Mottas I, Rötzer LC, Oberson A, Spagnuolo L, Perdicchio M, Spinetti T, Herbst T, Bourquin C. Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses. Oncoimmunology 2016;5:e1232219. [PMID: 27999742 DOI: 10.1080/2162402X.2016.1232219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
13 Yang M, Larson PG, Brown L, Schultz JR, Kucaba TA, Griffith TS, Ferguson DM. Toll-like Receptor 7 and 8 Imidazoquinoline-Based Agonist/Antagonist Pairs. Bioorganic & Medicinal Chemistry Letters 2022. [DOI: 10.1016/j.bmcl.2022.128548] [Reference Citation Analysis]
14 Grimmig T, Moench R, Kreckel J, Haack S, Rueckert F, Rehder R, Tripathi S, Ribas C, Chandraker A, Germer CT, Gasser M, Waaga-Gasser AM. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. Int J Mol Sci 2016;17:E2060. [PMID: 27941651 DOI: 10.3390/ijms17122060] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
15 Gurudas Shivji G, Dhar R, Devi A. Role of Exosomes and its emerging therapeutic applications in the pathophysiology of Non-Infectious disease. Biomarkers 2022;:1-53. [PMID: 35451890 DOI: 10.1080/1354750X.2022.2067233] [Reference Citation Analysis]
16 Chen YC, Hsiao CC, Chen KD, Hung YC, Wu CY, Lie CH, Liu SF, Sung MT, Chen CJ, Wang TY, Chang JC, Tang P, Fang WF, Wang YH, Chung YH, Chao TY, Leung SY, Su MC, Wang CC, Lin MC. Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PLoS One 2013;8:e57053. [PMID: 23451142 DOI: 10.1371/journal.pone.0057053] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
17 Mukhopadhyay I, Kulkarni A, Aranake S, Karnik P, Shetty M, Thorat S, Ghosh I, Wale D, Bhosale V, Khairatkar-Joshi N. Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic. PLoS One 2014;9:e97005. [PMID: 24819048 DOI: 10.1371/journal.pone.0097005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
18 Thiyagarajan D, Fismen S, Seredkina N, Jacobsen S, Elung-Jensen T, Kamper AL, Fenton CG, Rekvig OP, Mortensen ES. Silencing of renal DNaseI in murine lupus nephritis imposes exposure of large chromatin fragments and activation of Toll like receptors and the Clec4e. PLoS One 2012;7:e34080. [PMID: 22479529 DOI: 10.1371/journal.pone.0034080] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
19 Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun 2017;8:14600. [PMID: 28300057 DOI: 10.1038/ncomms14600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
20 Wu H, Gao H, Li A, Xie Y, Jia Z, Yang Z, Zhang H, Zhang Z, Zhang X. Impact of Genetic Variation in TLR4 3'UTR on NSCLC Genetic Susceptibility. J Oncol 2020;2020:7593143. [PMID: 32351566 DOI: 10.1155/2020/7593143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Mol Cancer Ther 2016;15:1740-5. [PMID: 27196764 DOI: 10.1158/1535-7163.MCT-15-0931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Arora S, Ahmad S, Irshad R, Goyal Y, Rafat S, Siddiqui N, Dev K, Husain M, Ali S, Mohan A, Syed MA. TLRs in pulmonary diseases. Life Sci 2019;233:116671. [PMID: 31336122 DOI: 10.1016/j.lfs.2019.116671] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
23 Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93:847-863. [PMID: 23475577 DOI: 10.1189/jlb.1012501] [Cited by in Crossref: 188] [Cited by in F6Publishing: 175] [Article Influence: 20.9] [Reference Citation Analysis]
24 Chi H, Li C, Zhao FS, Zhang L, Ng TB, Jin G, Sha O. Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol 2017;8:304. [PMID: 28620298 DOI: 10.3389/fphar.2017.00304] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 15.4] [Reference Citation Analysis]
25 Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015;6:1359-1381. [PMID: 25682197 DOI: 10.18632/oncotarget.3204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
26 Rodriguez C, Veciana C. ASTHMA AND COVID-19: THE EOSINOPHILIC LINK. Qeios. [DOI: 10.32388/5iy4if] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Gañán-Gómez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, Boyano-Adánez Mdel C, García-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One 2014;9:e93404. [PMID: 24690917 DOI: 10.1371/journal.pone.0093404] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
28 Ding R, Jiao A, Zhang B. Targeting toll-like receptors on T cells as a therapeutic strategy against tumors. International Immunopharmacology 2022;107:108708. [DOI: 10.1016/j.intimp.2022.108708] [Reference Citation Analysis]
29 Zhang Y, Yang H, Barnie PA, Yang P, Su Z, Chen J, Jiao Z, Lu L, Wang S, Xu H. The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. Int J Med Sci 2014;11:608-13. [PMID: 24782650 DOI: 10.7150/ijms.8428] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
30 Jiang J, Dong L, Qin B, Shi H, Guo X, Wang Y. Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells. Oncol Lett 2016;12:631-6. [PMID: 27347192 DOI: 10.3892/ol.2016.4617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Grimmig T, Matthes N, Hoeland K, Tripathi S, Chandraker A, Grimm M, Moench R, Moll EM, Friess H, Tsaur I, Blaheta RA, Germer CT, Waaga-Gasser AM, Gasser M. TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int J Oncol 2015;47:857-66. [PMID: 26134824 DOI: 10.3892/ijo.2015.3069] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
32 Ye J, Ma C, Hsueh EC, Dou J, Mo W, Liu S, Han B, Huang Y, Zhang Y, Varvares MA, Hoft DF, Peng G. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med 2014;6:1294-311. [PMID: 25231413 DOI: 10.15252/emmm.201403918] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
33 Fabbri M, Paone A, Calore F, Galli R, Croce CM. A new role for microRNAs, as ligands of Toll-like receptors. RNA Biol. 2013;10:169-174. [PMID: 23296026 DOI: 10.4161/rna.23144] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 11.0] [Reference Citation Analysis]
34 Drake MG, Evans SE, Dickey BF, Fryer AD, Jacoby DB. Toll-like receptor-2/6 and Toll-like receptor-9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs. Am J Respir Cell Mol Biol 2013;48:790-6. [PMID: 23449736 DOI: 10.1165/rcmb.2012-0498OC] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
35 Branchi V, Esser L, Boden C, Jafari A, Henn J, Lingohr P, Gonzalez-Carmona MA, Schmitz M, Weismüller TJ, Strassburg CP, Manekeller S, Kristiansen G, Kalff JC, Matthaei H, Toma MI. A Combined TLR7/TLR9/GATA3 Score Can Predict Prognosis in Biliary Tract Cancer. Diagnostics (Basel) 2021;11:1597. [PMID: 34573939 DOI: 10.3390/diagnostics11091597] [Reference Citation Analysis]
36 Baglivo S, Bianconi F, Metro G, Gili A, Tofanetti FR, Bellezza G, Ricciuti B, Mandarano M, Teti V, Siggillino A, Reda MS, Chiari R, Pistola L, Sidoni A, Minotti V, Roila F, Ludovini V. Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes (Basel) 2021;12:992. [PMID: 34209514 DOI: 10.3390/genes12070992] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer 2017;141:1222-30. [PMID: 28569041 DOI: 10.1002/ijc.30810] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
38 Javaid N, Choi S. Toll-like Receptors from the Perspective of Cancer Treatment. Cancers (Basel) 2020;12:E297. [PMID: 32012718 DOI: 10.3390/cancers12020297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
39 Li W, Gao LN, Song PP, You CG. Development and validation of a RNA binding protein-associated prognostic model for lung adenocarcinoma. Aging (Albany NY) 2020;12:3558-73. [PMID: 32087603 DOI: 10.18632/aging.102828] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
40 Sarhadi S, Sadeghi S, Nikmanesh F, Pilehvar Soltanahmadi Y, Shahabi A, Fekri Aval S, Zarghami N. A Systems Biology Approach Provides Deeper Insights into Differentially Expressed Genes in Taxane-Anthracycline Chemoresistant and Non-Resistant Breast Cancers. Asian Pac J Cancer Prev 2017;18:2629-36. [PMID: 29072056 DOI: 10.22034/APJCP.2017.18.10.2629] [Reference Citation Analysis]
41 Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012;122:4118-4129. [PMID: 23023703 DOI: 10.1172/jci63606] [Cited by in Crossref: 119] [Cited by in F6Publishing: 79] [Article Influence: 13.2] [Reference Citation Analysis]
42 Lin LL, Liu ZZ, Tian JZ, Zhang X, Zhang Y, Yang M, Zhong HC, Fang W, Wei RX, Hu C. Integrated Analysis of Nine Prognostic RNA-Binding Proteins in Soft Tissue Sarcoma. Front Oncol 2021;11:633024. [PMID: 34026613 DOI: 10.3389/fonc.2021.633024] [Reference Citation Analysis]
43 Dajon M, Iribarren K, Cremer I. Dual roles of TLR7 in the lung cancer microenvironment. Oncoimmunology 2015;4:e991615. [PMID: 25949912 DOI: 10.4161/2162402X.2014.991615] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
44 Barh D, Tiwari S, Kumavath RN, Ghosh P, Azevedo V. Linking common non-coding RNAs of human lung cancer and M. tuberculosis. Bioinformation 2018;14:337-45. [PMID: 30237679 DOI: 10.6026/97320630014337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Stathopoulos A, Pretto C, Devillers L, Pierre D, Hofman FM, Kruse C, Jadus M, Chen TC, Schijns VE. Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. Oncoimmunology 2012;1:298-305. [PMID: 22737605 DOI: 10.4161/onci.19068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
46 Liu M, Zeng X, Wang J, Fu Z, Wang J, Liu M, Ren D, Yu B, Zheng L, Hu X, Shi W, Xu J. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis. Stem Cell Res Ther 2016;7:63. [PMID: 27107963 DOI: 10.1186/s13287-016-0319-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
47 Braunstein MJ, Kucharczyk J, Adams S. Targeting Toll-Like Receptors for Cancer Therapy. Target Oncol 2018;13:583-98. [PMID: 30229471 DOI: 10.1007/s11523-018-0589-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 14.7] [Reference Citation Analysis]
48 Gu J, Liu Y, Xie B, Ye P, Huang J, Lu Z. Roles of toll-like receptors: From inflammation to lung cancer progression. Biomed Rep 2018;8:126-32. [PMID: 29435270 DOI: 10.3892/br.2017.1034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
49 Sun M, Bai Y, Zhao S, Liu X, Gao Y, Wang L, Liu B, Ma D, Ma C. Gram-negative bacteria facilitate tumor progression through TLR4/IL-33 pathway in patients with non-small-cell lung cancer. Oncotarget 2018;9:13462-73. [PMID: 29568370 DOI: 10.18632/oncotarget.24008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
50 Sahoo S, Singh P, Kalha B, Singh O, Pal R. Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets. BMC Cancer. 2015;15:931. [PMID: 26608647 DOI: 10.1186/s12885-015-1938-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
51 Bauer AK, Upham BL, Rondini EA, Tennis MA, Velmuragan K, Wiese D. Toll-like receptor expression in human non-small cell lung carcinoma: potential prognostic indicators of disease. Oncotarget 2017;8:91860-75. [PMID: 29190881 DOI: 10.18632/oncotarget.19463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
52 Dutta D, Lim SH. Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions. Biomark Res. 2020;8:31. [PMID: 32817793 DOI: 10.1186/s40364-020-00211-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
53 Chesson CB, Zloza A. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine (Lond) 2017;12:2693-706. [PMID: 29098928 DOI: 10.2217/nnm-2017-0254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
54 Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:699-716. [PMID: 22934262 DOI: 10.4161/onci.20696] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 153.0] [Reference Citation Analysis]
55 Liotti F, Marotta M, Sorriento D, Pone E, Morra F, Melillo RM, Prevete N. Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:740. [PMID: 33578955 DOI: 10.3390/cancers13040740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Shadhu K, Xi C. Inflammation and pancreatic cancer: An updated review. Saudi J Gastroenterol 2019;25:3-13. [PMID: 30588953 DOI: 10.4103/sjg.SJG_390_18] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
57 Jeon YK, Kim CK, Koh J, Chung DH, Ha GH. Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination. Oncotarget 2016;7:41811-24. [PMID: 27248820 DOI: 10.18632/oncotarget.9619] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
58 Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien VR. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology. 2012;1:326-333. [PMID: 22737608 DOI: 10.4161/onci.18852] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 77.0] [Reference Citation Analysis]
59 Muccioli M, Sprague L, Nandigam H, Pate M, Benencia F. Toll-like receptors as novel therapeutic targets for ovarian cancer. ISRN Oncol 2012;2012:642141. [PMID: 22530148 DOI: 10.5402/2012/642141] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
60 Hosoya T, Sato-Kaneko F, Ahmadi A, Yao S, Lao F, Kitaura K, Matsutani T, Carson DA, Hayashi T. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist. Proc Natl Acad Sci U S A 2018;115:E6836-44. [PMID: 29967183 DOI: 10.1073/pnas.1803281115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
61 Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley AG, McArdle SEB. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Front Immunol 2020;11:615240. [PMID: 33679703 DOI: 10.3389/fimmu.2020.615240] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
62 Gosu V, Basith S, Kwon OP, Choi S. Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling. Molecules 2012;17:13503-29. [PMID: 23151919 DOI: 10.3390/molecules171113503] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
63 Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H, Liu Z. Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy 2014;10:257-68. [PMID: 24321786 DOI: 10.4161/auto.27162] [Cited by in Crossref: 109] [Cited by in F6Publishing: 116] [Article Influence: 12.1] [Reference Citation Analysis]
64 Javaid N, Yasmeen F, Choi S. Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods. Pharmaceutics 2019;11:E441. [PMID: 31480568 DOI: 10.3390/pharmaceutics11090441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
65 Huang L, Xu H, Peng G. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Cell Mol Immunol 2018;15:428-37. [PMID: 29553135 DOI: 10.1038/cmi.2018.4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 15.0] [Reference Citation Analysis]
66 Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene 2017;36:4037-46. [PMID: 28288138 DOI: 10.1038/onc.2017.47] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
67 Brzóska K, Sochanowicz B, Siomek A, Oliński R, Kruszewski M. Alterations in the expression of genes related to NF-κB signaling in liver and kidney of CuZnSOD-deficient mice. Mol Cell Biochem 2011;353:151-7. [PMID: 21472504 DOI: 10.1007/s11010-011-0781-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
68 Gowing SD, Cool-Lartigue JJ, Spicer JD, Seely AJE, Ferri LE. Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence. Clin Exp Metastasis 2020;37:225-39. [PMID: 31975313 DOI: 10.1007/s10585-020-10018-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
69 Deng S, Zhu S, Qiao Y, Liu YJ, Chen W, Zhao G, Chen J. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell 2014;5:899-911. [PMID: 25411122 DOI: 10.1007/s13238-014-0112-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
70 Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860-875. [PMID: 23151605 DOI: 10.1038/nrc3380] [Cited by in Crossref: 902] [Cited by in F6Publishing: 884] [Article Influence: 90.2] [Reference Citation Analysis]
71 Shah D, Comba A, Faisal SM, Kadiyala P, Baker GJ, Alghamri MS, Doherty R, Zamler D, Nuñez G, Castro MG, Lowenstein PR. A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. Oncoimmunology 2021;10:1939601. [PMID: 34249474 DOI: 10.1080/2162402X.2021.1939601] [Reference Citation Analysis]
72 Huang XY, Sun WY, Yan ZQ, Shi HR, Yang QL, Wang PF, Li SG, Liu LX, Zhao SG, Gun SB. Novel Insights reveal Anti-microbial Gene Regulation of Piglet Intestine Immune in response to Clostridium perfringens Infection. Sci Rep 2019;9:1963. [PMID: 30760749 DOI: 10.1038/s41598-018-37898-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
73 Menendez D, Shatz M, Azzam K, Garantziotis S, Fessler MB, Resnick MA. The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet 2011;7:e1001360. [PMID: 21483755 DOI: 10.1371/journal.pgen.1001360] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 8.3] [Reference Citation Analysis]
74 Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(32): 3745-3751 [PMID: 21990957 DOI: 10.3748/wjg.v17.i32.3745] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
75 Shahbaz MA, Martikainen MV, Rönkkö TJ, Komppula M, Jalava PI, Roponen M. Urban air PM modifies differently immune defense responses against bacterial and viral infections in vitro. Environ Res 2021;192:110244. [PMID: 32980306 DOI: 10.1016/j.envres.2020.110244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Liu X, Xu Q, Li Z, Xiong B. Integrated analysis identifies AQP9 correlates with immune infiltration and acts as a prognosticator in multiple cancers. Sci Rep 2020;10:20795. [PMID: 33247170 DOI: 10.1038/s41598-020-77657-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
77 Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology 2019;8:e1505174. [PMID: 30546943 DOI: 10.1080/2162402X.2018.1505174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
78 Linnebacher M, Maletzki C, Klier U, Klar E. Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg 2012;397:557-68. [PMID: 22189906 DOI: 10.1007/s00423-011-0892-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
79 Riva F, Bonavita E, Barbati E, Muzio M, Mantovani A, Garlanda C. TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity. Front Immunol 2012;3:322. [PMID: 23112799 DOI: 10.3389/fimmu.2012.00322] [Cited by in Crossref: 45] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]